Item Type | Name |
Concept
|
Multiple Myeloma
|
Academic Article
|
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
|
Academic Article
|
Clinician attitudes and practices toward measurable residual disease in multiple myeloma.
|
Academic Article
|
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma.
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
|
Academic Article
|
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
|
Academic Article
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
|
Academic Article
|
Sex differences in outcomes in multiple myeloma.
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
Academic Article
|
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
|
Academic Article
|
Knowing the unknowns in high risk multiple myeloma.
|
Academic Article
|
ATTR Cardiomyopathy Meets Multiple Myeloma: The Importance of Cardiac Biopsy.
|
Academic Article
|
When a Monoclonal Gammopathy Is Not Multiple Myeloma.
|
Academic Article
|
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.
|
Academic Article
|
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
|
Academic Article
|
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
|
Academic Article
|
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma.
|
Academic Article
|
Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma.
|
Academic Article
|
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
|
Academic Article
|
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
|
Concept
|
Smoldering Multiple Myeloma
|
Academic Article
|
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.
|
Academic Article
|
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
|
Academic Article
|
Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma.
|
Academic Article
|
MRD-guided treatment cessation in multiple myeloma.
|
Academic Article
|
Measurable Residual Disease and Decision-Making in Multiple Myeloma.
|
Academic Article
|
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
|
Academic Article
|
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
|
Academic Article
|
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
|
Academic Article
|
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
|
Academic Article
|
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
|
Academic Article
|
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
|
Academic Article
|
Improving Access to T-Cell Therapies in Multiple Myeloma.
|